Jade Biosciences, Inc. (JBIO) vs Rigel Pharmaceuticals, Inc. (RIGL)
Jade Biosciences, Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Jade Biosciences, Inc. and Rigel Pharmaceuticals, Inc. are of similar size ($936.8M and $894.6M). Jade Biosciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.7×. Rigel Pharmaceuticals, Inc. has the higher net margin (116.3% vs 0.00%) and the higher return on invested capital (16.5% vs 0.00%). Across the 13 metrics below, Rigel Pharmaceuticals, Inc. leads on 11 and Jade Biosciences, Inc. on 2.
Valuation
Profitability
| Metric | JBIO | RIGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 91.39% | 65.16% |
| Operating margin | 0.00% | 31.45% | 0.00% |
| Net margin | 0.00% | 116.30% | 0.00% |
| Free cash flow margin | 0.00% | 3.19% | 0.00% |
| Return on equity | (39.27%) | 126.90% | (57.72%) |
| Return on assets | (36.19%) | 88.46% | (49.22%) |
| Return on invested capital | 0.00% | 16.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack